Form 4: Sutro Biopharma CEO's Routine Stock Transactions

Sutro Biopharma CEO Jane Chung reported the vesting and net settlement of 788 restricted stock units, increasing her direct common stock ownership.

Summary

• CEO Jane Chung reported transactions on March 4, 2026, involving Sutro Biopharma, Inc. (STRO) common stock.
• 788 Restricted Stock Units (RSUs) vested and were subsequently settled.
• Upon settlement, 788 shares of Common Stock were acquired by Ms. Chung.
• 282 shares of Common Stock were withheld by Sutro Biopharma at a price of $21.31 per share to satisfy income tax withholding obligations related to the RSU settlement.
• Following these transactions, Jane Chung directly owns 21,285 shares of Sutro Biopharma Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting the routine operation of executive compensation plans and continued insider ownership, which aligns management interests with shareholders.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates continued service and commitment from the Chief Executive Officer.
• The transaction aligns the CEO's financial interests with the long-term performance of the company through equity ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that RSU vesting and net settlement are standard compensation practices for executives in the biotechnology industry, aligning executive incentives with long-term company performance and are routine disclosures.

Comparison to Industry Standards

• RSU vesting and net settlement are common executive compensation practices across the biotechnology industry and broader public markets, aligning executive incentives with long-term company performance.
• This transaction is consistent with typical compensation structures for CEOs of publicly traded biopharma companies, where equity awards form a significant part of total compensation.

Related Party Transactions

• The settlement of Restricted Stock Units (RSUs) involves a transaction between the company and its Chief Executive Officer, Jane Chung, as part of her compensation package.

Stakeholder Impact

• Shareholders: The vesting and settlement of RSUs are part of the company's approved compensation plan, which can lead to minor dilution but also aligns management's interests with long-term shareholder value.
• Management: Jane Chung's compensation includes equity, aligning her incentives with the company's long-term performance and strategic goals.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction related to executive compensation (RSU vesting and tax withholding). It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is an expected part of executive compensation plans and does not signal any material shift in the company's prospects.

Keywords

Sutro Biopharma, STRO, Jane Chung, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Compensation, CEO, Beneficial Ownership